Articles On Imugene (ASX:IMU)

Australian stocks were poised to open lower following declines on Wall Street as strong jobs growth dented hopes for a pause in interest rate increases later this year. ASX futures retreated 32 points or 0.44 per cent, signalling early p...

Highlights At market close, Australian shares dropped 0.8%, or 58.1 points, to 7175.9. Tech stocks dragged the benchmark index lower, followed by healthcare. Australia’s April trade surplus came in higher than expected. Daily mark...

ASX closes 0.8% lower BHP-Woodside merged company, Woodside Energy makes its ASX trading debut today OPEC meeting ahead    The ASX 200 dropped right from the opening bell, and finished the day lower by 0.80% to 7,175. All 11 sectors fell...

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of surgical oncologist Dr Yanghee Woo to its scientific advisory board.

ASX 200 finished flattish by 0.08% today Green metal miners plunge after a Goldman Sachs report says the bull run is over for lithium Aussie GDP was higher than expected   Local shares finished flattish today despite the fall on Wall Stre...

Highlights The iron ore futures price rose 0.1% to US$133.60 a tonne on Monday as China relaxed COVID-19 curbs. The rise in iron ore price seems to have pushed the materials sector higher, which was one of the three sectors trading in...

ASX 200 was up 0.56% today Investors flock to gold stocks on flight to safety Tech stocks plunge 2.5% as risk aversion kicks in   The benchmark ASX 200 index closed 0.56% higher today as investors flocked into gold stocks. It was a flight...

ShareCafeEvening Report: 24 May, 2022 by Melissa Darmawan   Australian shares ran out of steam and closed at session lows as investors mulled on whether the fresh stimulus from Beijing is enough to offset China’s lockdowns as tech shares se...

ASX 200 is down 0.30% The Lottery Corp makes its debut on the ASX  Tech weighs heavily after Snap Inc warning   The ASX 200 traded in a volatile range today, but ended the day down by 0.3%. The index was up by 0.20% but was not able to ho...

The share market fell away late in the session as a collapse in US equity futures cooled expectations for tonight’s Wall Street action. The S&P/ASX 200 finished 20 points or 0.28 per cent lower after treading water for much of the se...

Australian shares marked time after a poorly-received trading update from US social media giant Snap sharpened doubts about the outlook for corporate earnings as costs increase and the economy slows. The S&P/ASX 200 struggled to get...

Highlights ASX 200 closed today’s trade merely 3.30 points up at 7,148.90 points. Materials supported gains against the pulldown from financials and utilities. Incitec Pivot, Imugene, and Elders were some newsmakers of the day. St...

ShareCafeEvening Report: 23 May, 2022 by Melissa Darmawan   The Aussie sharemarket lost steam from midday and eked out a gain after hearing that Beijing reported a record number of Covid-19 cases, renewing concerns the capital may face anot...

ASX closes flat Mining and Energy lead, while Health and Financials lag Codan, Elders offer strong guidance The first day of a new government didn’t have much impact on the local stock market, with Aussie blue chips closing the day flat....

The share market gave up most of its early gains as overseas crosswinds overshadowed Saturday’s federal election result. The S&P/ASX 200 gained as much as 50 points in early action before trimming its advance to three points or 0.05...

Australian immune-oncology stock Imugene [ASX:IMU] released a letter this morning addressing shareholder discontent at the recent share price decline. The post Imugene [ASX:IMU] Shares Rise as Management Seeks to Reassure Shareholders appea...

The Imugene Limited (ASX: IMU) share price is soaring ahead today. At the time of writing, Imugene shares are swapping hands for 22.8 cents, a 13.75% gain. In contrast, the S&P/ASX 200 Health Care Index (ASX: XHJ) is 0.87% in the red...

The share market trimmed strong early gains as record Covid cases in Beijing triggered profit-taking after the market briefly climbed 50 points in the wake of Saturday’s federal election. At the halfway mark, the S&P/ASX 200 was down...

The chairman highlighted the company’s strong cash reserves and broad clinical portfolio as assets that would help it weather the storm.

ShareCafeLunch Report: 23 May, 2022 by Melissa Darmawan   Australian stocks extend their relief-rally, following Anthony Albanese sworn in as Australia’s 31st prime minister. Nationals voted in a new government that has earmarked climate ch...

ShareCafeEvening Report: 19 May, 2022 by Melissa Darmawan   More pain for investors as a wave of selling on recession and inflation fears exacerbated by profit misses from retail giants Target and Walmart hit US markets, with the S&P/AS...

Highlights ASX 200 closed 1.6% lower in a session marked by sharp declines for consumer-facing companies. The decline tailed a drop in US shares that wiped 4% from the S&P 500 index of blue chips, the worst day in approximately two...

Aussie small cap index falls 1.4% The ASX200 down 1.65% Thursday is Arafura Day!   Down less than 2% and I think we can call that a win. No one likes the sight of blood and after the major Wall Street indices shed more than 3.5% a piece,...

The Imugene Limited (ASX: IMU) share price took off today despite the company’s silence. However, today’s gains might have been a belated reaction to the news the company announced to the ASX yesterday. As of Thursday’s close, the Imugene...

Blue-chip retailers suffered bruising losses after a corporate profit scare pushed the ASX sharply lower. Bunnings owner Wesfarmers, Woolworths and Coles spearheaded falls as the S&P/ASX 200 slumped 118 points or 1.65 per cent. Th...

Markets may be tanking but there are two ASX shares on the All Ordinaries Index (ASX: XAO) that are shooting the lights out on Thursday. The two have surged by more than 10% each – an impressive gain on any day. But it’s particularly notab...

ShareCafeLunch Report: 19 May, 2022 by Melissa Darmawan   Consumer staples and discretionary stocks are leading the dive on the Australian sharemarket, shrugging off the improved labour market and giving back three days of gains. Bunnings a...

The share market gave up almost three days of gains after renewed inflation worries triggered Wall Street’s worst sell-off since 2020. The S&P/ASX 200 tumbled 102 points or 1.42 per cent by mid-session. Ten of 11 sectors declined....

At lunch on Thursday, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of Wall Street and is tumbling notably lower. The benchmark index is currently down 1.55% to 7,072 points. Here’s what is happening on the ASX 200 today: Aris...

Highlights: The benchmark index ASX200 was down 1.75% in opening trade on Thursday Overnight selloff on Wall Street spooked investors and impacted risk sentiments All the 11 sectors on the ASX are in the red today Australian equit...

Imugene (IMU) doses its first patient in a phase one clinical trial to shrink advanced tumours The company, in collaboration with City of Hope, dosed the first patient in a trial evaluating the safety of the novel cancer-killing virus, whi...

ASX is set to open higher after a Wall Street rally US Fed chairman Jerome Powell says the Fed will keep pushing until inflation declines Crucial Aussie unemployment data due out tomorrow Aussie shares are set to open higher this morning...

ShareCafeEvening Report: 16 May, 2022 by Lauren Evans   Australian shares struggled to maintain their early morning rally after China revealed that it had suffered an 11.1 per cent drop in retail sales during April, which was worse than exp...

Highlights ASX 200 closed up, gaining 17.90 points or 0.25% to 7,093.00. China’s decision to lock down major cities amid worries about Covid-19 resurgence could strain supply chains; Russia’s invasion of Ukraine continues to raise ener...

Blue chips pare gains after downbeat Chinese economic data Industrial sector jumps after speculation about a takeover attempt of Brambles Bitcoin and the crypto market have stabilised   Asian markets reacted negatively to China’s latest e...

The S&P/ASX 200 Index (ASX: XJO) is having a reasonably positive start to the week. In afternoon trade, the benchmark index is up 0.35% to 7,100 points. Four ASX shares that have failed to follow the market higher today are listed belo...

ShareCafeLunch Report: 16 May, 2022 by Lauren Evans   The Aussie sharemarket has advanced this morning buoyed by a jump in Brambles (ASX:BXB) and tech shares. This comes after an optimistic finish on Wall Street, which saw a relief-rally fo...

At lunch on Monday, the S&P/ASX 200 Index (ASX: XJO) has started the week on a reasonably positive note. The benchmark index is currently up 0.3% to 7,096.5 points. Here’s what is happening on the ASX 200 today: Goodman Q3 update impre...

A relief rally lifted the ASX 200 back above the 7000 level as a pause in this week’s bloodletting on Wall Street brought buyers back to market. The S&P/ASX 200 bounced 95 points or 1.36 per cent to 7036 by mid-session. The rally bro...

The share market slumped to a 15-week low before partially recovering as rising US futures sharpened hopes of a relief rally tonight. The S&P/ASX 200 finished 69.5 points or 0.98 per cent in the red at 7051 after trading as low as 69...

Fears of a global slowdown helped drive the share market to its lowest since January before a partial mid-morning recovery.   The S&P/ASX 200 dropped more than 2.5 per cent in early action before buyers stepped in. By mid-session the...

Emyria announced progress on its MDMA (ecstasy) program Imugene gets green light for a Phase 2 Australian clinical trial Beamtree wins US$7m deal   Emyria Limited (ASX: EMD) has announced positive progress on its MDMA (also known as ‘ecst...

Immuno-oncology company Imugene (ASX:IMU) has announced it has received Human Research Ethics Committee approval to commence a Phase 2 clinical trial of its immunotherapy candidate, HER-Vaxx in Australia.

ASX to open extend losses as Wall Street crashes again Oil prices plunge 9% as EU ban on Russian oil fails to gain approval Aussie dollar plunges below US70c   The ASX 200 is set to extend its losses for a third consecutive day, following...

Imugene (IMU) receives Human Research Ethics Committee (HREC) approval to start a phase two clinical trial of its cancer vaccine, HER-Vaxx in Australia This approval confirms the company has completed pre-clinical safety and efficacy for t...

Highlights ASX 200 finished today’s session down 1.2% or 84.90 points to 7.120, The index was dragged lower by real estate, technology, and materials sectors. Rate worries, continued supply-side pressures, and a tightening lockdown in...

Imugene has rejected suggestions it was slow to update the market after copping its second notice from the ASX about the cancellation of a deal.

ASX 200 extended loss, down by 1.43% All sectors fell except for Energy Tech and Real Estate were the worst performers   The ASX has extended its selloff as local stocks closed to the lowest level in two months. At the close, the benchmar...

The share market closed at a seven-week low as soft Chinese economic data pushed the dollar below 70 US cents and sapped buying interest in mining stocks. The S&P/ASX 200 shed 85 points or 1.18 per cent. Today’s close was the weakest...

In late trade, the S&P/ASX 200 Index (ASX: XJO) looks set to record a disappointing decline. At the time of writing, the benchmark index is down 1.4% to 7,102.9 points. Four ASX shares that are falling more than most are listed below....